Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 30,000 Shares

Posted by Francis Steltz on Aug 6th, 2026

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) insider Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total transaction of $914,400.00. Following the completion of the transaction, the insider directly owned 54,645 shares of the company’s stock, valued at approximately $1,665,579.60. This trade represents a 35.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO traded up $0.23 during trading on Thursday, reaching $31.95. 1,078,223 shares of the company’s stock were exchanged, compared to its average volume of 1,061,327. The business has a 50 day moving average price of $34.66 and a 200-day moving average price of $30.97. The stock has a market capitalization of $1.91 billion, a P/E ratio of -4.56 and a beta of 0.58. Agios Pharmaceuticals, Inc. has a fifty-two week low of $22.24 and a fifty-two week high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%.The business had revenue of $44.75 million for the quarter, compared to the consensus estimate of $26.39 million. On average, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.12 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on AGIO shares. JPMorgan Chase & Co. lowered their target price on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a research note on Thursday, June 11th. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Bank of America raised their target price on Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. HC Wainwright upped their price objective on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Finally, Truist Financial reduced their target price on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Five research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $40.88.

Read Our Latest Stock Analysis on Agios Pharmaceuticals

Institutional Trading of Agios Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. acquired a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at about $25,000. Assetmark Inc. raised its stake in shares of Agios Pharmaceuticals by 37.9% in the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 362 shares during the last quarter. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals in the first quarter valued at approximately $40,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $49,000. Finally, Eurizon Capital SGR S.p.A. bought a new stake in Agios Pharmaceuticals during the fourth quarter worth $72,000.

About Agios Pharmaceuticals

(Get Free Report)

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.